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Poster Session I S229Hospital Anxiety and Depression Scale (HADS) and Lawton and
Brody’s instrumental activities of daily living.
Apart from age, both cohorts were well matched for baseline char-
acteristics. The median age of patients undergoing RIC was signifi-
cantly higher to those undergoing MY conditioning (59 vs. 42 yrs,
p\0.0001). The compliance for completion of QOL assessments
was: baseline, 98%; Day30, 91%; day100, 85%; day180, 84%; and
day365, 85%. The main reason for non-compliance was illness due
to toxicity or disease relapse.
QOL data were analyzed for both cohorts without imputation.
QOL scores did not differ for the two study groups at baseline.
There was a decline in QOL scores in post transplant period
with lowest scores at day30 followed by subsequent slow improve-
ment to baseline by day365. The RIC cohort had better QLQ-
C30 scores in the domains of physical functioning (p5 0.005)
and role functioning (p5 0.02) at day30. No other significant dif-
ferences were noted between the two groups at other time points.
Recovery post transplant was similar in the two cohorts. In a mul-
tivariate analysis, clinically meaningful differences in favor of RIC
cohort were observed in the role functioning domain of QLQ-
C30. In addition, patients with HCT-comorbidity scores$ 3
had significantly worse scores for emotional functioning and
global health domain of QLQC-30, FACT-BMT, FACT-An
and HADS.
Imputing QOL data using worst scores for patients who did not
complete QOL questionnaire due to illness did not significantly in-
fluence the above results.
We conclude that both MY and RIC regimens resulted in similar
QOL at 1-year post transplant.191
IMPLEMENTATION OF A HEMATOLOGICAL MALIGNANCY-BASED SURVI-
VORSHIP CLINIC
Asher, A., Steinberg, A. Cedars-Sinai Medical Center, Los Angeles, CA
Background: There are approximately 12 million cancer survivors
in the U.S. Cancer survivors are at increased risk for health compli-
cations such as heart disease, secondary malignancies, and psycho-
logical distress. Reflecting the needs of cancer survivors as part of
our health care system, the Institute of Medicine issued a seminal re-
port, From Cancer Patient to Cancer Survivor: Lost in Transition,
recognizing cancer survivorship as a ‘‘distinct phase of cancer
care.’’ A dedicated survivorship clinic with creation of personal
care plans and treatment summaries can serve the needs of this grow-
ing cohort of patients.
Objective: To determine the viability of a transplant/hematological
malignancy-based survivorship clinic with treatment summary and
care plan for survivors.
Methods: A literature search was initiated examining recommenda-
tions and guidelines regarding follow-up of cancer patients. We in-
corporated and consolidated guidelines from ASCO, NMDP,
NCCN, and COG, pertinent articles from the PubMed database,
and the growing literature for cancer survivorship. Awareness of
the program was to be initiated with letters to affiliated physicians,
lecture series, patient-oriented educational handouts, and articles
in the hospital literature.
Data Synthesis: A treatment care plan was devised for all survi-
vorship clinic patients. This care plan summarized patients’ prior
care with recommendations for follow-up such as cardiac and can-
cer screening, osteoporosis, thyroid disease, and vaccination
schedules–all based on our consolidative review of available evi-
dence-based or expert guidelines. A referral base was developed
with specialists focused on lymphedema, psychiatric issues (needs
determined by screening tools), social work, art therapy, exercise,
and nutrition.
Results: Patients from affiliated hematologists/oncologists were
seen in the survivorship clinic. Unique care plans were devised for
them based on their history of having had a hematologic malignancy
or a stem cell transplant. A satisfaction survey was to be imple-
mented. Preliminary satisfaction from both physicians and the pa-
tients themselves was positive.Conclusion: A transplant/hematologic malignancy-based survivor-
ship clinic is feasible and fills an important need in a large, urban,
hospital-based cancer center. Further investigation will focus on de-
veloping a computer-based treatment summary and care plan, in-
creasing patient referrals, and developing a lecture series devoted
to survivorship.192
OUTCOME OF SOLID ORGAN TRANSPLANT FOLLOWING BLOOD AND
MARROW TRANSPLANT (BMT) IN PEDIATRIC PATIENTS
Guzikowski, V., Bunin, N. Children’s Hospital of Philadelphia, PA
Blood and marrow transplant (BMT) may be curative for children
with malignancies as well as life-threatening non-malignant diseases.
However, permanent organ failure may result from conditioning
regimens or other BMT-related toxicities. Solid organ transplant
(SOT) may be indicated for a select group of pediatric patients,
but this poses difficult decisions for families and caregivers. There
is limited information available about the outcome of children who
received SOT following BMT. At the Children’s Hospital of Phila-
delphia, we have identified eight children (4 males) who have re-
ceived a solid organ transplant following a BMT. Patients (pts)
were 6 months to 18 years at the time of BMT. Diseases for which
BMT was indicated included: thalassemia, Wiskott-Adrich syn-
drome, Shwachman-Diamond/bone marrow failure, sickle cell dis-
ease (SCD), erythopoetic porphyria (EP), acute lymphoblastic
leukemia, chronic granulamotous disease, and neuroblastoma. BM
donors were matched sibling in 4, unrelated in 3, and autologous
for one. Time from BMT to SOT was 13 days-7 years (median, 27
months), with two pts\2 months who received liver transplants. In-
dications for liver transplant included VOD (2), chronic GVHD
(1).Lung SOT was performed for 2 pts with bronchiolitis obliterans
(2), and kidney transplants for 3 pts with renal failure. Three of the
organs were from a living related donor (2- liver, 1-kidney), and 5
were cadaveric organs. Four pts were on immunosuppressant agents
at the time of the SOT: 2 pts\2 months from BMT on a cyclospor-
ine infusion, one pt on tacrolimus for treatment of BOOP, and one pt
with EP on both azathioprine and prednisone due to a previous liver
transplant. Seven pts (2-lungs, 2-liver, 3-kidney) are alive with func-
tioning allografts two to 157 months from SOT. One pt with thalas-
semia developed multiple mesenteric artery thromboses following
two attempts at liver transplant and died. Advances in organ procure-
ment, operative technique, immunosuppressant therapy and infec-
tion control may allow SOT for a select group of pts post BMT.
However, scarcity of donor organs available in a timely fashion
continues to be a limiting factor. Children who have undergo
BMT and develop single organ failure should be considered for
a solid organ transplant if there is a high likelihood of cure of the
primary disease.193
FIRST DESCRIPTION OF A SUCCESSFUL PREGNANCY AFTERMYELOABLA-
TIVE STEM CELL TRANSPLANTATION IN A SICKLE CELL PATIENT BY
MEANS OF AN OVARIAN TISSUE AUTOGRAFT
Roux, C.1,5, Amiot, C.1,5, Agnani, G.2, Aubard, Y.3, Deconinck, E.4,5,
Piver, P.3, Rohrlich, P.S.4,5 1CHU Hopital Saint Jacques, Besancon,
France; 2CHU Hopital Saint Jacques, Besancon, France; 3CHU Hopital
Me`re et Enfant, Limoges, France; 4CHUHopital Jean Minjoz, Besancon,
France; 5UMR 645 INSERM/UFC/EFS BFC, Besancon, France
The preservation of fertility is an emerging concern in patients
treated by myeloablative hematopoietic stem cell transplantation
(HSCT). One major drawback of autologous gonadic tissue trans-
plant being the risk of leukemia recurrence, this procedure is first
to be proposed to patients allografted for non malignant diseases.
Cryopreservation of ovarian tissue with subsequent autotransplanta-
tion is an emerging procedure that has led to 6 reported births until
today, none of them being obtained after HSCT. Moreover, 3 of
these 6 pregnancies were obtained through in vitro fertilization pro-
cedures. We report the restoration of ovarian activity followed by
pregnancy and live birth after an orthotopic transplantation of ovar-
ian tissue in a 19 year old female patient transplanted for sickle cell
anemia. The patient having experienced a CNS stroke received an
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after ovarian tissue cryopreservation. The conditioning regimen in-
cluded IV busulfan (12.8 mg/kg total dose), cyclophosphamide
(200 mg/kg total dose) and antilymphocyte globulin. A stable
100% donor chimerism was obtained from D60. An acute grade II
GVHD was followed by limited chronic GVHD for 7 months. Clin-
ical menopause with amenorrhoea due to premature ovarian failure
occured within the first year post-HSCT. Hormone replacement
with oestro-progestogens was started 6 months after HSCT and
was maintained until ovarian function restoration. In spring 2008,
as the patient had been menopausal for 2.5 years, an orthotopic au-
totransplantation of ovarian cortex was performed in two consecu-
tive laparoscopic procedures, the first one being aimed at inducing
local angiogenesis. One thawed strip of ovarian cortex was fixed in
the ovarian incision, 5 others were deposited in the peritoneal win-
dow. Three days later, 3 thawed cortical strips were fixed into the
left ovary and one into the peritoneal window. Ovarian function re-
covery was evaluated by hormonal levels and follicular development
was observed by ultrasound.
The patient conceived spontaneously in a natural cycle in autumn
2008, and delivered a healthy child in June 2009. This first case re-
port of pregnancy and delivery after ovarian autograft in a patient
treated by HSCT suggests that cryopreservation of ovarian tissue
should be offered prior to HSCT not only to women of childbearing
age but also to prepubertal patients, as primordial follicles are al-
ready present in the post natal ovaries.194
EXTRACORPOREAL PHOTOPHERESIS IN PATIENTS WITH BRONCHIOLI-
TIS OBLITERANS DEVELOPING AFTER ALLOGENEIC STEM CELL TRANS-
PLANTATION
Lucid, C.1, Engelhardt, B.1, Shah, P.2, Clifton, C.1, Vaughan, L.A.1,
Kassim, A.1, Goodman, S.1, Schuening, F.1, Jagasia, M.1,
Savani, B.N.1 1Vanderbilt University Medical Center, Nashville, TN;
2Vanderbilt University Medical Center, Nashville, TN
Background: Nearly 90% of the patients who are alive 2 years af-
ter allogeneic SCT (allo-SCT) will become long term survivors
and the focus of care moves to the long term complications.
Chronic graft-versus-host-disease (cGVHD) has attracted the
most attention, especially non-infectious pulmonary complication
bronchiolitis obliterans (BO). Extracorporeal Photopheresis
(ECP), has been shown to be a promising treatment for cGVHD,
however, only a few case reports are available that examines the ef-
fectiveness of ECP for BO.
Methods:Nine patients received ECP between 7/2008-8/2009 after
median follow-up of 23 months (range 9-93) for symptomatic BO
who failed immunosuppressive therapy and combination with azi-
thromycin, inhaled steroids6montelucast sodium. Records were re-
viewed to determine the impact of ECP on BO in an IRB-approved
study. Patients were treated on a weekly basis with 2 pheresis sessions
a week (3 to 4 weeks) and then decreased to an every 2 to 4 week
interval. (Jagasia et al Biol Blood Marrow Transplant 2009;15:
1288-95).
Results: All except one patient received allo-SCT for hematological
malignancies. The median age was 38 years (range 21-54), and 5 were
female. Patients received allo-SCT between 1/2002- 6/2008 from
matched related (n5 5) or unrelated donor (n5 4); conditioning
consisted TBI based myeloablative regimens in 7 patients. GVHD
prophylaxis consisted of calcineurin inhibitors and methotraxate or
mycophenolate. Grade II-IV aGVHD occurred in 8 patients, grade
III in 1. All patients experienced cGVHD, 3 patients had 5 organ in-
volvements (median 3, range 1-5). Pre-ECP cGVHD pulmonary
subscale score was 3 in 4 (44%) patients. Median time to BO was
17 months post-transplant (range 5-46). All patients had minimum
of 4 drug regimens prior to ECP (median 5, range 4-6) for BO man-
agement. Median time to ECP following diagnosis of BO was 3
months (range 1-54). Eight of 9 (89%) responded to ECP after a me-
dian of 25 days (range 20-958). One patient who did not qualify as
responder had stabilization in FEV1 but continue to remain symp-
tomatic after 108 day on ECP. Three of 4 patients with pulmonary
cGVHD score of 3 responded to addition of ECP.Conclusion: Our case series shows that addition of ECP to com-
monly used regimen for BO results in faster symptomatic improve-
ment in an otherwise debilitating long term complication after
allo- SCT. A limitation of this study is a small sample size, short fol-
low-up, however impressive clinical response.LEUKEMIA
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IMATINIB MAINTENANCE FOLLOWING ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLANTATION (HCT) FOR PATIENTS WITH PHILADELPHIA
CHROMOSOME POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA
(ALL)
Kebriaei, P.1, Chiattone, A.1, Saliba, R.1, Jones, D.2, Anderlini, P.1,
Andersson, B.1, Khouri, I.1, Worth, L.3, Ravandi, F.4, Thomas, D.4,
Kantarjian, H.4, Hamerschlak, N.5, Rodrigues, M.5, de Lima, M.1,
Giralt, S.1, Champlin, R.1 1University of Texas M.D. Anderson Cancer
Center, Houston, TX; 2University of Texas M.D. Anderson Cancer Cen-
ter, Houston, TX; 3University of Texas M.D. Anderson Cancer Center,
Houston, TX; 4University of Texas M.D. Anderson Cancer Center, Hous-
ton, TX; 5Albert Einstein Israeli Hospital (HIAE), Sao Paulo, Brazil
The addition of tyrosine kinase inhibitors (TKI) to conventional
ALL therapy has significantly improved outcome for Ph+ patients,
resulting in more patients being able to receive HCT in remission.
Maintenance therapy with TKI following HCT may additionally
improve outcomes. We performed a retrospective chart review on
transplants since 2001 when TKI first became available for use fol-
lowing HCT. From March 2001 through June 2009, 66 patients
with median age 37 years (range 3-61) received an allogeneic HCT
for Ph+ ALL in CR1 (n5 56) or CR2 (n5 10); 28 patients were in
complete molecular remission at time of HCT. Patients received
matched related (n5 30) or matched unrelated (n5 27) peripheral
blood (n5 35), bone marrow (n5 22), or mismatched cord blood
cells (n5 9) following a myeloablative TBI-based (n5 48) or non-
TBI-based (n5 18) transplant conditioning regimen. GVHD pro-
phylaxis was tacrolimus-based. All patients received TKI prior to
HCT. Patients were eligible to receive TKI maintenance following
HCT if they had hematologic recovery defined by an unsupported
platelet count .50,000/uL and absolute neutrophil count .1500/
uL. Forty-seven percent (n5 31) of patients received TKI in the
form of imatinib at median dose 300 mg (range 100-800) initiated
at median of 2 months (range 1-12) following HCT. Median dura-
tion of imatinib use post HCT was 13 months (range 1-91). The
most common reason for treatment discontinuation was physician
preference followed by disease progression. Cytopenias and gastro-
intestinal discomfort were the most common imatinib-related toxic-
ities. With a median follow-up of 4 years among survivors (range 0.3-
7.7), 2-year overall survival (OS) and progression-free survival (PFS)
were 55% and 50%, respectively. Day 100, 1-year, and 2-year non-
relapse mortality (NRM) rates were 11%, 26%, and 28%, respec-
tively. The cumulative incidence of grade 2-4 and 3-4 acute
GVHD were 48% and 16%, respectively; the incidence of chronic
extensive GVHD was 19%. In univariate analysis, imatinib mainte-
nance led to significantly better OS (HR 0.3, 95% CI 0.1-.8,
p5 0.02) and NRM (HR 0.3, 95%CI 0.1-1.1, p5 0.07). Addition-
ally, age. 40 years and CR2 vs CR1 led to significantly worse OS;
molecular remission did not reach statistical significance. Large,
multicenter trials in Ph+ ALL are in progress to confirm the benefit
of TKI maintenance following HCT.196
DEVELOPING A MURINE MODEL TO STUDY B CELLS AS APC IN VIVO
Liebig, T.M.1, Shimabukuro-Vornhagen, A.1, Klein-Gonzalez, N.1,
Wickenhauser, C.2, Kondo, E.3, von Bergwelt-Baildon, M.1 1University
Hospital of Cologne, NRW, Germany; 2University Hospital of Cologne,
NRW, Germany; 3Okayama University Hospital, Okayama, Japan
Introduction: As Dendritic cells (DC) are effective conductors of
adaptive and innate immune responses, they are used as cellular ad-
juvant for active immunotherapy. Nevertheless, challenges to this
